Source: Pharmabiz

Avid Radiopharmaceuticals: Eli Lilly announces positive results from phase 3 study of PET imaging agent, flortaucipir F 18

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc, a wholly owned subsidiary of Lilly, announced that a phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
100-250
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



Avid Radiopharmaceuticals, Inc., is a Private company. Avid Radiopharmaceuticals, Inc.,'s parent company has been Lilly Eli & Co since Dec 2011.